PDCD1 and neoplasm: Changes in model components such as the parental tumor type, model antigen, model TCR, level of tumor PD-L1 expression, and anti-PD-1 dosing schedule did not change the central finding that endogenous T cells were required for PD-1 blockade to mediate therapeutic benefit.